CellVoyant is a biotechnology firm dedicated to harnessing artificial intelligence and live cell imaging to predict and optimize stem cell differentiation. Founded in 2022, it emerged from the Carazo Salas lab at the University of Bristol and is backed by notable venture capital investors. The company aims to address critical health challenges by creating novel stem cell-based therapies, contributing to both research and therapeutic advancements. At CellVoyant, the team is focused on collaboration, cutting-edge innovation, and making a meaningful impact on chronic diseases. The working environment encourages interdisciplinary teamwork and prioritizes an inclusive culture where scientific exploration thrives. By combining expertise in biology and machine learning, CellVoyant is at the forefront of developing solutions that could transform health care outcomes.